Archive WILEX Adhoc and Press Releases 2011

ENGLISH DEUTSCH

Selected press releases and adhocs of the former years can be found here.

14 December 2011 PR: WILEX and IBA report on follow up meeting with the FDA on further steps in the development of REDECTANE®
07 December 2011 PR: WILEX Inc. lists Oncogene Science® CA IX IHC Kit as an In-Vitro-Diagnostic with the FDA
21 November 2011 PR: WILEX AG: ARISER Independent Data Monitoring Committee (IDMC) recommends conducting the final analysis of the pivotal Phase III trial with RENCAREX®
AH: WILEX AG: ARISER Independent Data Monitoring Committee (IDMC) recommends conducting the final analysis of the pivotal Phase III trial with RENCAREX®
14 October 2011 AH: WILEX reports an adjustment of the goodwill of Heidelberg Pharma AG according to IFRS
13 October 2011 PR: WILEX publishes 9-month financial report 2011
10 October 2011 PR: WILEX Inc. and ALPCO Diagnostics sign marketing and distribution agreement for North America
05 October 2011 PR: FDA grants Fast Track designation to WILEX’s RENCAREX® for the adjuvant therapy of clear cell Renal Cell Carcinoma
15 September 2011 PR: WILEX starts first oral Phase I study with MEK inhibitor WX-554
03 August 2011 PR: WILEX’s subsidiary WILEX Inc. receives ISO certification
14 July 2011 PR: WILEX announces successful half year results
17 June 2011 PR: WILEX and IBA report on the Pre-BLA Meeting with the FDA and the next steps in the REDECTANE® approval process
AH: WILEX reports on the Pre-BLA Meeting with the FDA and the next steps in the REDECTANE® approval process
05 May 2011 PR: Patient recruitment in Phase II breast cancer trial with MESUPRON® successfully completed
02 May 2011 PR: WILEX grants exclusive US commercialisation rights for RENCAREX® to Prometheus
29 April 2011 AH: WILEX grants exclusive US commercialisation rights for RENCAREX® to Prometheus
13 April 2011 PR: WILEX reports on successful first half year 2010
22 February 2011 PR: WILEX reports on the successful financial year 2010
24 January 2011 PR: WILEX announces start of interim analysis for its Phase III ARISER registration trial with RENCAREX®
Seite gelesen: 477 | Heute: 4